Health And Family

Novavax vaccine highly effective against severe COVID-19 — company

Agence France-Presse
Novavax vaccine highly effective against severe COVID-19 â company
(FILES) In this file illustration picture shows vials with Covid-19 Vaccine stickers attached and syringes with the logo of US biotech company Novavax, on November 17, 2020. US biotech firm Novavax's Covid-19 vaccine was shown to be 100 percent protective against severe cases of the disease, including hospitalization and death, the company said on March 11, 2021 following trials.
AFP/Justin Tallis

WASHINGTON, United States — US biotech firm Novavax's Covid-19 vaccine was shown to be 100 percent protective against severe cases of the disease, including hospitalization and death, the company said Thursday following trials.

But its efficacy against the South African variant fell markedly when including mild and moderate cases, results showed.

The results announced Thursday were from final analyses, following interim results that were announced in late January.

In a Phase 3 trial in Britain that included 15,000 participants aged 18-84, including 27 percent over the age of 65, efficacy against mild, moderate and severe Covid was 96.4 percent against the original strain.

This fell to 89.7 when including people infected with the  B.1.1.7 variant, which has been shown to be more transmissible and cause more severe disease. 

In South Africa, a smaller Phase 2b trial of some 2,600 people found it was 48.6 percent effective, though the figure rose to 55.4 percent among HIV-negative volunteers.

Across both trials, the vaccine known as NVX-CoV2373 demonstrated 100 percent protection against severe disease.

Unlike the Pfizer, Moderna and AstraZeneca vaccines, which deliver the genetic instructions that make human cells create a key protein of the virus, the Novavax shot injects synthetic versions of these proteins directly into the body to evoke an immune response.

The Maryland-based company has said it hopes to file for British approval of its Covid-19 vaccine at the start of the second quarter of 2021, and to do the same soon after in the United States.

As It Happens
LATEST UPDATE: September 24, 2021 - 2:16pm

Pharma giants Sanofi and GSK said on July 29, 2020, that they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract."

This thread collects some of the major developments in the search for a vaccine to ease the new coronavirus pandemic. (Main photo by AFP/Joel Saget)

September 24, 2021 - 2:16pm

A committee of US health experts declines to approve Pfizer booster shots for individuals at high risk of COVID-19 exposure due to their jobs, despite authorization from a different agency just the night before. 

The decision has contributed to growing confusion about the campaign for booster doses in the United States, which the administration of President Joe Biden announced in mid-August but has since lost momentum. 

The Centers for Disease Control and Prevention (CDC) committee voted Thursday to recommend a third dose of Pfizer's vaccine for people over age 65 and for those with underlying conditions who are at risk of developing a severe case of COVID-19. — AFP

September 23, 2021 - 7:50am

The United States authorizes the use of boosters of Pfizer's Covid-19 vaccine for people aged over 65, people at high-risk of severe disease and those in high-exposure settings to the virus.

"Today's action demonstrates that science and the currently available data continue to guide the FDA’s decision-making for COVID-19 vaccines during this pandemic," says Janet Woodcock, acting head of the Food and Drug Administration. — AFP

September 22, 2021 - 8:18am

COVID-19 vaccine manufacturers are putting profit before lives, Amnesty International says, as it demands two billion doses for poorer nations by the end of the year.

The human rights group says in a new report that US President Joe Biden was expected to outline a pledge at the UN General Assembly to fully vaccinate 70% of the world's population by next September.

"We need leaders like President Biden to put billions of doses on the table and deliver the goods, otherwise this is just another empty gesture and lives will continue to be lost," Amnesty chief Agnes Callamard says.

September 18, 2021 - 9:14am

A panel of leading US medical experts advising the government vote in favor of authorizing boosters of Pfizer's coronavirus vaccine for everyone aged 65 and up, as well as people at high risk of developing severe Covid.

The same committee however rejected an initial proposal, submitted by Pfizer and backed by President Joe Biden's administration, to fully approve boosters to everyone aged 16 and over. 

The decisions came after a day-long meeting full of data presentations and at times charged debate that was convened by the Food and Drug Administration (FDA). Tens of millions of Americans will soon be eligible for a third shot. — AFP

September 17, 2021 - 12:51pm

US medical experts will meet Friday to debate and vote on the controversial question of giving out booster doses of Pfizer's Covid-19 vaccine to the general population.

President Joe Biden's administration announced in August a plan to roll out third shots to everyone, not just the immune compromised already able to receive them, starting from September 20. 

But experts have since expressed reservations about whether they are required, amid concerns over global inequity, the greater need to vaccinate the unvaccinated, and possible increased risk of side effects. — AFP

  • Latest
Are you sure you want to log out?

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

or sign in with